{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T03:54:07Z","timestamp":1782273247086,"version":"3.54.5"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:00:00Z","timestamp":1633478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:00:00Z","timestamp":1633478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Spinal muscular atrophy (SMA) is a severe childhood neuromuscular disease for which two genetic therapies, Nusinersen (Spinraza, an antisense oligonucleotide), and AVXS-101 (Zolgensma, an adeno-associated viral vector of serotype 9 AAV9), have recently been approved. We investigated the pre-clinical development of SMA genetic therapies in rodent models and whether this can predict clinical efficacy. We have performed a systematic review of relevant publications and extracted median survival and details of experimental design. A random effects meta-analysis was used to estimate and compare efficacy. We stratified by experimental design (type of genetic therapy, mouse model, route and time of administration) and sought any evidence of publication bias. 51 publications were identified containing 155 individual comparisons, comprising 2573 animals in total. Genetic therapies prolonged survival in SMA mouse models by 3.23-fold (95% CI 2.75\u20133.79) compared to controls. Study design characteristics accounted for significant heterogeneity between studies and greatly affected observed median survival ratios. Some evidence of publication bias was found. These data are consistent with the extended average lifespan of Spinraza- and Zolgensma-treated children in the clinic. Together, these results support that SMA has been particularly amenable to genetic therapy approaches and highlight SMA as a trailblazer for therapeutic development.<\/jats:p>","DOI":"10.1038\/s41434-021-00292-4","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T20:37:31Z","timestamp":1633639051000},"page":"498-512","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Systematic review and meta-analysis determining the benefits of in vivo genetic therapy in spinal muscular atrophy rodent models"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8362-8850","authenticated-orcid":false,"given":"Ellie M.","family":"Chilcott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evalyne W.","family":"Muiruri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore C.","family":"Hirst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7113-1938","authenticated-orcid":false,"given":"Rafael J.","family":"Y\u00e1\u00f1ez-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,6]]},"reference":[{"key":"292_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, Burgen L, Reboullet S, Clermont O, Burlet P, Viollet L, et al. Identification and characterisation of a spinal muscular atrophy-determining gene. Cell. 1995;80:155\u201365.","journal-title":"Cell."},{"key":"292_CR2","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.neuron.2005.12.001","volume":"48","author":"UR Monani","year":"2005","unstructured":"Monani UR. Spinal muscular atrophy: a deficiency in a ubiquitous protein; a motor neuron specific disease. Neuron. 2005;48:885\u201396.","journal-title":"Neuron."},{"key":"292_CR3","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1242\/dmm.030148","volume":"10","author":"M Bowerman","year":"2017","unstructured":"Bowerman M, Becker CG, Y\u00e1\u00f1ez-Mu\u00f1oz RJ, Ning K, Wood M, Gillingwater TH, et al. Therapeutic strategies for spinal muscular atrophy: SMN and beyond. Disease Models Mechanisms. 2017;10:943\u201354.","journal-title":"Disease Models Mechanisms"},{"key":"292_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/ana.24864","volume":"81","author":"MA Farrar","year":"2017","unstructured":"Farrar MA, Park SB, Vucic S, Carey KA, Turner BJ, Gillingwater TH, et al. Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol. 2017;81:355\u201368.","journal-title":"Ann Neurol"},{"key":"292_CR5","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1097\/NEN.0b013e3181a10ea1","volume":"68","author":"R Martinez-Hernandez","year":"2009","unstructured":"Martinez-Hernandez R, Soler-Botija C, Also E, Alias L, Caselles L, Gich I, et al. The developmental pattern of myotubes in spinal muscular atrophy indicates prenatal delay of muscle maturation. J Neuropathol Experimental Neurol. 2009;68:474\u201381.","journal-title":"J Neuropathol Experimental Neurol"},{"key":"292_CR6","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/mus.21654","volume":"42","author":"S Rudnik-Schoneborn","year":"2010","unstructured":"Rudnik-Schoneborn S, Vogelgesang S, Armbrust S, Graul-Neumann L, Fusch C, Zerres K. Digital necroses and vascular thrombosis in severe spinal muscular atrophy. Muscle Nerve. 2010;42:144\u20137.","journal-title":"Muscle Nerve"},{"key":"292_CR7","doi-asserted-by":"crossref","unstructured":"Wijngaarde CA, Blank AC, Stam M, Wadman RI, van den Berg LH, van der Pol WL. Cardiac pathology in spinal muscular atrophy: a systematic review. Orphanet J Rare Dis. 2017;12:67.","DOI":"10.1186\/s13023-017-0613-5"},{"key":"292_CR8","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1007\/s00439-006-0156-7","volume":"119","author":"B Wirth","year":"2006","unstructured":"Wirth B, Brichta L, Schrank B, Lochmuller H, Blick S, Baasner A, et al. Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet. 2006;119:422\u20138.","journal-title":"Hum Genet"},{"key":"292_CR9","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/gt.2017.52","volume":"24","author":"K Talbot","year":"2017","unstructured":"Talbot K, Tizzano EF. The clinical landscape for SMA in a new therapeutic era. Gene Ther. 2017;24:529\u201333.","journal-title":"Gene Ther"},{"key":"292_CR10","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N. Eng J Med. 2017;377:1713\u201322.","journal-title":"N. Eng J Med"},{"key":"292_CR11","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1056\/NEJMoa2009965","volume":"384","author":"G Baranello","year":"2021","unstructured":"Baranello G, Darras BT, Day JW, Deconinck N, Klein A, Masson R, et al. Risdiplam in type 1 spinal muscular atrophy. N. Eng J Med. 2021;384:915\u201323.","journal-title":"N. Eng J Med"},{"key":"292_CR12","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jneumeth.2013.09.010","volume":"221","author":"HM Vesterinen","year":"2014","unstructured":"Vesterinen HM, Sena ES, Egan KJ, Hirst TC, Churolov L, Currie GL, et al. Meta-analysis of data from animal studies: a practical guide. J Neurosci Methods. 2014;221:92\u2013102.","journal-title":"J Neurosci Methods"},{"key":"292_CR13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/bjc.2012.504","volume":"108","author":"TC Hirst","year":"2013","unstructured":"Hirst TC, Vesterinen HM, Sena ES, Egan KJ, Macleod MR, Whittle IR. Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted? Br J Cancer. 2013;108:64\u201371.","journal-title":"Br J Cancer"},{"key":"292_CR14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1017\/S0266462305050154","volume":"21","author":"S Michiels","year":"2005","unstructured":"Michiels S, Piedbois P, Burdett S, Syz N, Stewart L, Pignon JP. Meta-analysis when only the median survival times are known: a comparison with individual patient data results. Int J Technol Assess Health Care. 2005;21:119\u201325.","journal-title":"Int J Technol Assess Health Care"},{"key":"292_CR15","doi-asserted-by":"crossref","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8.","DOI":"10.1186\/1745-6215-8-16"},{"key":"292_CR16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird NM. Meta-analysis in clinical trials. Controll Clin Trials. 1986;7:177\u201388.","journal-title":"Controll Clin Trials"},{"key":"292_CR17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cct.2015.09.002","volume":"45","author":"R DerSimonian","year":"2015","unstructured":"DerSimonian R, Laird NM. Meta-analysis in clinical trials revisted. Contemperary Clin Trials. 2015;45:139\u201345.","journal-title":"Contemperary Clin Trials"},{"key":"292_CR18","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J. 1997;315:629\u201334.","journal-title":"Br Med J"},{"key":"292_CR19","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","volume":"56","author":"S Duval","year":"2000","unstructured":"Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455\u201363.","journal-title":"Biometrics."},{"key":"292_CR20","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/jama.295.6.676","volume":"295","author":"JL Peters","year":"2006","unstructured":"Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295:676\u201380.","journal-title":"JAMA"},{"key":"292_CR21","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1093\/hmg\/ddp076","volume":"18","author":"TD Baughan","year":"2009","unstructured":"Baughan TD, Dickson A, Osman EY, Lorson CL. Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophy. Hum Mol Genet. 2009;18:1600\u201311.","journal-title":"Hum Mol Genet"},{"key":"292_CR22","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1523\/JNEUROSCI.4489-09.2010","volume":"30","author":"TH Coady","year":"2010","unstructured":"Coady TH, Lorson CL. Trans-splicing-mediated improvement in a severe mouse model of spinal muscular atrophy. J Neurosci. 2010;30:126\u201330.","journal-title":"J Neurosci"},{"key":"292_CR23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1089\/hum.2010.114","volume":"22","author":"M Shababi","year":"2011","unstructured":"Shababi M, Glascock J, Lorson C. Combination of SMN trans -splicing and a neurotrophic factor increases the life span and body mass in a severe model of spinal muscular atrophy. Hum Gene Therapy. 2011;22:135\u201344.","journal-title":"Hum Gene Therapy"},{"key":"292_CR24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nature10485","volume":"478","author":"Y Hua","year":"2011","unstructured":"Hua Y, Sahashi K, Rigo F, Hung G, Horev G, Bennett CF, et al. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature. 2011;478:123\u20136.","journal-title":"Nature."},{"key":"292_CR25","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1126\/scitranslmed.3001777","volume":"3","author":"MA Passini","year":"2011","unstructured":"Passini MA, Bu J, Richards AM, Kinnecom C, Sardi SP, Stanek LM, et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med. 2011;3:72.","journal-title":"Sci Transl Med"},{"key":"292_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/mt.2011.232","volume":"20","author":"EY Osman","year":"2012","unstructured":"Osman EY, Yen PF, Lorson CL. Bifunctional RNAs targeting the intronic splicing silencer N1 increase SMN levels and reduce disease severity in an animal model of spinal muscular atrophy. Mol Ther. 2012;20:119\u201326.","journal-title":"Mol Ther"},{"key":"292_CR27","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1093\/hmg\/ddr600","volume":"21","author":"PN Porensky","year":"2012","unstructured":"Porensky PN, Mitrpant C, McGovern VL, Bevan AK, Foust KD, Kaspar BK, et al. A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse. Hum Mol Genet. 2012;21:1625\u201338.","journal-title":"Hum Mol Genet"},{"key":"292_CR28","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1089\/hum.2012.211","volume":"24","author":"H Zhou","year":"2013","unstructured":"Zhou H, Janghra N, Mitrpant C, Dickinson RL, Anthony K, Price L, et al. A novel morpholino oligomer targeting ISS-N1 improves rescue of severe spinal muscular atrophy transgenic mice. Hum Gene Ther. 2013;24:331\u201342.","journal-title":"Hum Gene Ther"},{"key":"292_CR29","doi-asserted-by":"publisher","first-page":"e174","DOI":"10.1038\/mtna.2014.23","volume":"3","author":"JM Keil","year":"2014","unstructured":"Keil JM, Seo J, Howell MD, Hsu WH, Singh RN, DiDonato CJ. A short antisense oligonucleotide ameliorates symptoms of severe mouse models of spinal muscular atrophy. Mol Ther Nucleic Acids. 2014;3:e174.","journal-title":"Mol Ther Nucleic Acids"},{"key":"292_CR30","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.clinthera.2014.02.004","volume":"36","author":"M Nizzardo","year":"2014","unstructured":"Nizzardo M, Simone C, Salani S, Ruepp MD, Rizzo F, Ruggieri M, et al. Effect of combined systemic and local morpholino treatment on the spinal muscular atrophy Delta7 mouse model phenotype. Clin Ther. 2014;36:340\u201356.e5.","journal-title":"Clin Ther"},{"key":"292_CR31","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1093\/hmg\/ddu198","volume":"23","author":"EY Osman","year":"2014","unstructured":"Osman EY, Miller MR, Robbins KL, Lombardi AM, Atkinson AK, Brehm AJ, et al. Morpholino antisense oligonucleotides targeting intronic repressor Element1 improve phenotype in SMA mouse models. Hum Mol Genet. 2014;23:4832\u201345.","journal-title":"Hum Mol Genet"},{"key":"292_CR32","doi-asserted-by":"publisher","first-page":"E5863","DOI":"10.1073\/pnas.1509758112","volume":"112","author":"LP Bogdanik","year":"2015","unstructured":"Bogdanik LP, Osborne MA, Davis C, Martin WP, Austin A, Rigo F, et al. Systemic, postsymptomatic antisense oligonucleotide rescues motor unit maturation delay in a new mouse model for type II\/III spinal muscular atrophy. PNAS USA. 2015;112:E5863\u201372.","journal-title":"PNAS USA"},{"key":"292_CR33","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1101\/gad.256644.114","volume":"29","author":"Y Hua","year":"2015","unstructured":"Hua Y, Liu YH, Sahashi K, Rigo F, Bennett CF, Krainer AR. Motor neuron cell-nonautonomous rescue of spinal muscular atrophy phenotypes in mild and severe transgenic mouse models. Genes Dev. 2015;29:288\u201397.","journal-title":"Genes Dev"},{"key":"292_CR34","doi-asserted-by":"publisher","first-page":"6265","DOI":"10.1093\/hmg\/ddv329","volume":"24","author":"HY Zhou","year":"2015","unstructured":"Zhou HY, Meng JH, Marrosu E, Janghra N, Morgan J, Muntoni F. Repeated low doses of morpholino antisense oligomer: an intermediate mouse model of spinal muscular atrophy to explore the window of therapeutic response. Hum Mol Genet. 2015;24:6265\u201377.","journal-title":"Hum Mol Genet"},{"key":"292_CR35","doi-asserted-by":"crossref","unstructured":"Olivan S, Calvo AC, Rando A, Herrando-Grabulosa M, Manzano R, Zaragoza P, et al. Neuroprotective Effect of Non-viral Gene Therapy Treatment Based on Tetanus Toxin C-fragment in a Severe Mouse Model of Spinal Muscular Atrophy. Front Mol Neurosci. 2016;9:76.","DOI":"10.3389\/fnmol.2016.00076"},{"key":"292_CR36","doi-asserted-by":"publisher","first-page":"10962","DOI":"10.1073\/pnas.1605731113","volume":"113","author":"SM Hammond","year":"2016","unstructured":"Hammond SM, Hazell G, Shabanpoor F, Saleh AF, Bowerman M, Sleigh JN, et al. Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy. PNAS USA. 2016;113:10962\u20137.","journal-title":"PNAS USA"},{"key":"292_CR37","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.ajhg.2016.07.014","volume":"99","author":"S Hosseinibarkooie","year":"2016","unstructured":"Hosseinibarkooie S, Peters M, Torres-Benito L, Rastetter RH, Hupperich K, Hoffmann A, et al. The power of human protective modifiers: PLS3 and CORO1C unravel impaired endocytosis in spinal muscular atrophy and rescue SMA phenotype. Am J Hum Genet. 2016;99:647\u201365.","journal-title":"Am J Hum Genet"},{"key":"292_CR38","doi-asserted-by":"crossref","unstructured":"Lin TL, Chen TH, Hsu YY, Cheng YH, Juang BT, Jong YJ. Selective Neuromuscular Denervation in Taiwanese Severe SMA Mouse Can Be Reversed by Morpholino Antisense Oligonucleotides. Plos One. 2016;11:e0154723.","DOI":"10.1371\/journal.pone.0154723"},{"key":"292_CR39","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/mt.2016.145","volume":"24","author":"EY Osman","year":"2016","unstructured":"Osman EY, Washington CW, Kaifer KA, Mazzasette C, Patitucci TN, Florea KM, et al. Optimization of morpholino antisense oligonucleotides targeting the intronic repressor element1 in spinal muscular atrophy. Mol Ther. 2016;24:1592\u2013601.","journal-title":"Mol Ther"},{"key":"292_CR40","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.nbd.2015.12.014","volume":"87","author":"W Arnold","year":"2016","unstructured":"Arnold W, McGovern VL, Sanchez B, Li J, Corlett KM, Kolb SJ, et al. The neuromuscular impact of symptomatic SMN restoration in a mouse model of spinal muscular atrophy. Neurobiol Dis. 2016;87:116\u201323.","journal-title":"Neurobiol Dis"},{"key":"292_CR41","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ajhg.2017.01.005","volume":"100","author":"M Riessland","year":"2017","unstructured":"Riessland M, Kaczmarek A, Schneider S, Swoboda KJ, Lohr H, Bradler C, et al. Neurocalcin delta suppression protects against spinal muscular atrophy in humans and across species by restoring impaired endocytosis. Am J Hum Genet. 2017;100:297\u2013315.","journal-title":"Am J Hum Genet"},{"key":"292_CR42","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1089\/nat.2016.0652","volume":"27","author":"F Shabanpoor","year":"2017","unstructured":"Shabanpoor F, Hammond SM, Abendroth F, Hazell G, Wood MJA, Gait MJ. Identification of a peptide for systemic brain delivery of a morpholino oligonucleotide in mouse models of spinal muscular atrophy. Nucleic Acid Ther. 2017;27:130.","journal-title":"Nucleic Acid Ther"},{"key":"292_CR43","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.neuron.2016.11.033","volume":"93","author":"C d\u2019Ydewalle","year":"2017","unstructured":"d\u2019Ydewalle C, Ramos DM, Pyles NJ, Ng SY, Gorz M, Pilato CM, et al. The antisense transcript SMN-AS1 regulates SMN expression and is a novel therapeutic target for spinal muscular atrophy. Neuron. 2017;93:66\u201379.","journal-title":"Neuron."},{"key":"292_CR44","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1093\/hmg\/ddg143","volume":"12","author":"JC Lesbordes","year":"2003","unstructured":"Lesbordes JC, Cifuentes-Diaz C, Miroglio A, Joshi V, Bordet T, Kahn A, et al. Therapeutic benefits of cardiotrophin-1 gene transfer in a mouse model of spinal muscular atrophy. Hum Mol Genet. 2003;12:1233\u20139.","journal-title":"Hum Mol Genet"},{"key":"292_CR45","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1172\/JCI22922","volume":"114","author":"M Azzouz","year":"2004","unstructured":"Azzouz M, Le T, Ralph GS, Walmsley L, Monani UR, Lee DC, et al. Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. J Clin Investig. 2004;114:1726\u201331.","journal-title":"J Clin Investig"},{"key":"292_CR46","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1172\/JCI41615","volume":"120","author":"MA Passini","year":"2010","unstructured":"Passini MA, Bu J, Roskelley EM, Richards AM, Sardi SP, O\u2019Riordan CR, et al. CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J Clin Investig. 2010;120:1253\u201364.","journal-title":"J Clin Investig"},{"key":"292_CR47","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1126\/scitranslmed.3000830","volume":"2","author":"CF Valori","year":"2010","unstructured":"Valori CF, Ning K, Wyles M, Mead RJ, Grierson AJ, Shaw PJ, et al. Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci Transl Med. 2010;2:35\u201342.","journal-title":"Sci Transl Med"},{"key":"292_CR48","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nbt.1610","volume":"28","author":"KD Foust","year":"2010","unstructured":"Foust KD, Wang XY, McGovern VL, Braun L, Bevan AK, Haidet AM, et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nature Biotechnology. 2010;28:271\u2013U126.","journal-title":"Nature Biotechnology"},{"key":"292_CR49","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/hmg\/ddq514","volume":"20","author":"E Dominguez","year":"2011","unstructured":"Dominguez E, Marais T, Chatauret N, Benkhelifa-Ziyyat S, Duque S, Ravassard P, et al. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Huma Mol Genet. 2011;20:681\u201393.","journal-title":"Huma Mol Genet"},{"key":"292_CR50","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1089\/hum.2011.166","volume":"23","author":"JJ Glascock","year":"2012","unstructured":"Glascock JJ, Osman EY, Wetz MJ, Krogman MM, Shababi M, Lorson CL. Decreasing disease severity in symptomatic, Smn(\u2212\/\u2212);SMN2(+\/+), spinal muscular atrophy mice following scAAV9-SMN delivery. Hum Gene Ther. 2012;23:330\u20135.","journal-title":"Hum Gene Ther"},{"key":"292_CR51","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.bbrc.2011.11.121","volume":"417","author":"JJ Glascock","year":"2012","unstructured":"Glascock JJ, Shababi M, Wetz MJ, Krogman MM, Lorson CL. Direct central nervous system delivery provides enhanced protection following vector mediated gene replacement in a severe model of spinal muscular atrophy. Biochem Biophys Res Commun. 2012;417:376\u201381.","journal-title":"Biochem Biophys Res Commun"},{"key":"292_CR52","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.yjmcc.2012.01.005","volume":"52","author":"M Shababi","year":"2012","unstructured":"Shababi M, Habibi J, Ma L, Glascock JJ, Sowers JR, Lorson CL. Partial restoration of cardio-vascular defects in a rescued severe model of spinal muscular atrophy. J Mol Cell Cardiol. 2012;52:1074\u201382.","journal-title":"J Mol Cell Cardiol"},{"key":"292_CR53","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/mt.2012.261","volume":"21","author":"S Benkhelifa-Ziyyat","year":"2013","unstructured":"Benkhelifa-Ziyyat S, Besse A, Roda M, Duque S, Astord S, Carcenac R, et al. Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice. Mol Ther. 2013;21:282\u201390.","journal-title":"Mol Ther"},{"key":"292_CR54","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1038\/mt.2014.84","volume":"22","author":"LK Tsai","year":"2014","unstructured":"Tsai LK, Chen CL, Ting CH, Lin-Chao S, Hwu WL, Dodge JC, et al. Systemic administration of a recombinant AAV1 vector encoding IGF-1 improves disease manifestations in SMA mice. Mol Ther. 2014;22:1450\u20139.","journal-title":"Mol Ther"},{"key":"292_CR55","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1089\/hum.2014.011","volume":"25","author":"MA Passini","year":"2014","unstructured":"Passini MA, Bu J, Richards AM, Treleaven CM, Sullivan JA, O\u2019Riordan CR, et al. Translational fidelity of intrathecal delivery of self-complementary AAV9-survival motor neuron 1 for spinal muscular atrophy. Hum Gene Ther. 2014;25:619\u201330.","journal-title":"Hum Gene Ther"},{"key":"292_CR56","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1093\/hmg\/ddu169","volume":"23","author":"KL Robbins","year":"2014","unstructured":"Robbins KL, Glascock JJ, Osman EY, Miller MR, Lorson CL. Defining the therapeutic window in a severe animal model of spinal muscular atrophy. Hum Mol Genet. 2014;23:4559\u201368.","journal-title":"Hum Mol Genet"},{"key":"292_CR57","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/mt.2014.209","volume":"23","author":"D Little","year":"2015","unstructured":"Little D, Valori CF, Mutsaers CA, Bennett EJ, Wyles M, Sharrack B, et al. PTEN depletion decreases disease severity and modestly prolongs survival in a mouse model of spinal muscular atrophy. Mol Ther. 2015;23:270\u20137.","journal-title":"Mol Ther"},{"key":"292_CR58","doi-asserted-by":"publisher","first-page":"e87908","DOI":"10.1172\/jci.insight.87908","volume":"1","author":"RA Powis","year":"2016","unstructured":"Powis RA, Karyka E, Boyd P, Come J, Jones RA, Zheng Y, et al. Systemic restoration of UBA1 ameliorates disease in spinal muscular atrophy. JCI Insight. 2016;1:e87908.","journal-title":"JCI Insight"},{"key":"292_CR59","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/mt.2016.152","volume":"24","author":"P Odermatt","year":"2016","unstructured":"Odermatt P, Trub J, Furrer L, Fricker R, Marti A, Schumperli D. Somatic Therapy of a Mouse SMA Model with a U7 snRNA Gene Correcting SMN2 Splicing. Mol Ther. 2016;24:1797\u2013805.","journal-title":"Mol Ther"},{"key":"292_CR60","doi-asserted-by":"publisher","first-page":"16060","DOI":"10.1038\/mtm.2016.60","volume":"3","author":"N Armbruster","year":"2016","unstructured":"Armbruster N, Lattanzi A, Jeavons M, Van Wittenberghe L, Gjata B, Marais T, et al. Efficacy and biodistribution analysis of intracerebroventricular administration of an optimized scAAV9-SMN1 vector in a mouse model of spinal muscular atrophy. Mol Ther Methods Clin Dev. 2016;3:16060.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"292_CR61","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.omtm.2018.01.007","volume":"9","author":"A Alrafiah","year":"2018","unstructured":"Alrafiah A, Karyka E, Coldicott I, Iremonger K, Lewis KE, Ning K, et al. Plastin 3 Promotes Motor Neuron Axonal Growth and Extends Survival in a Mouse Model of Spinal Muscular Atrophy. Mol Ther Methods Clin Dev. 2018;9:81\u20139.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"292_CR62","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1093\/hmg\/ddz188","volume":"28","author":"E Villalon","year":"2019","unstructured":"Villalon E, Kline RA, Smith CE, Lorson ZC, Osman EY, O\u2019Day S, et al. AAV9-Stathmin1 gene delivery improves disease phenotype in an intermediate mouse model of spinal muscular atrophy. Hum Mol Genet. 2019;28:3742\u201354.","journal-title":"Hum Mol Genet"},{"key":"292_CR63","doi-asserted-by":"publisher","first-page":"7618","DOI":"10.1093\/nar\/gkz469","volume":"47","author":"I Donadon","year":"2019","unstructured":"Donadon I, Bussani E, Riccardi F, Licastro D, Romano G, Pianigiani G, et al. Rescue of spinal muscular atrophy mouse models with AAV9-Exon-specific U1 snRNA. Nucleic Acids Res. 2019;47:7618\u201332.","journal-title":"Nucleic Acids Res"},{"key":"292_CR64","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/j.ymthe.2019.08.017","volume":"27","author":"A Rashnonejad","year":"2019","unstructured":"Rashnonejad A, Chermahini GA, Gunduz C, Onay H, Aykut A, Durmaz B, et al. Fetal gene therapy using a single injection of recombinant AAV9 Rescued SMA Phenotype in Mice. Mol Ther. 2019;27:2123\u201333.","journal-title":"Mol Ther"},{"key":"292_CR65","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1016\/j.celrep.2019.11.058","volume":"29","author":"CM Simon","year":"2019","unstructured":"Simon CM, Van Alstyne M, Lotti F, Bianchetti E, Tisdale S, Watterson DM, et al. Stasimon contributes to the loss of sensory synapses and motor neuron death in a mouse model of spinal muscular atrophy. Cell Rep. 2019;29:3885.","journal-title":"Cell Rep"},{"key":"292_CR66","doi-asserted-by":"crossref","unstructured":"Osman EY, Bolding MR, Villalon E, Kaifer KA, Lorson ZC, Tisdale S, et al. Functional characterization of SMN evolution in mouse models of SMA. Sci Rep. 2019;9:9472.","DOI":"10.1038\/s41598-019-45822-8"},{"key":"292_CR67","doi-asserted-by":"crossref","unstructured":"Ahlskog N, Hayler D, Krueger A, Kubinski S, Claus P, Hammond SM, et al. Muscle overexpression of Klf15 via an AAV8-Spc5-12 construct does not provide benefits in spinal muscular atrophy mice. Gene Ther. 2020;27:505\u201315.","DOI":"10.1038\/s41434-020-0146-8"},{"key":"292_CR68","doi-asserted-by":"crossref","unstructured":"Besse A, Astord S, Marais T, Roda M, Giroux B, Lejeune FX, et al. AAV9-mediated expression of SMN restricted to neurons does not rescue the spinal muscular atrophy phenotype in mice. Mol Ther. 2020;28:1887\u2013901.","DOI":"10.1016\/j.ymthe.2020.05.011"},{"key":"292_CR69","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s00401-020-02133-x","volume":"139","author":"M Nizzardo","year":"2020","unstructured":"Nizzardo M, Taiana M, Rizzo F, Benitez JA, Nijssen J, Allodi I, et al. Synaptotagmin 13 is neuroprotective across motor neuron diseases. Acta Neuropathol. 2020;139:837\u201353.","journal-title":"Acta Neuropathol"},{"key":"292_CR70","doi-asserted-by":"publisher","first-page":"e89970","DOI":"10.1172\/jci.insight.89970","volume":"2","author":"KA Kaifer","year":"2017","unstructured":"Kaifer KA, Villalon E, Osman EY, Glascock JJ, Arnold LL, Cornelison DDW, et al. Plastin-3 extends survival and reduces severity in mouse models of spinal muscular atrophy. JCI Insight. 2017;2:e89970.","journal-title":"JCI Insight"},{"key":"292_CR71","doi-asserted-by":"crossref","unstructured":"Zhou HY, Meng JH, Malerba A, Catapano F, Sintusek P, Jarmin S, et al. Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy. J Cachexia Sarcopenia Muscle. 2020;11:768\u201382.","DOI":"10.1002\/jcsm.12542"},{"key":"292_CR72","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/71709","volume":"24","author":"HM Hsieh-Li","year":"2000","unstructured":"Hsieh-Li HM, Chang JG, Jong YJ, Wu MH, Wang NM, Tsai CH, et al. A mouse model for spinal muscular atrophy. Nat Genet. 2000;24:66\u201370.","journal-title":"Nat Genet"},{"key":"292_CR73","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/hmg\/ddi078","volume":"14","author":"TT Le","year":"2005","unstructured":"Le TT, Pham LT, Butchbach MER, Zhang HL, Monani UR, Coovert DD, et al. SMN Delta 7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum Mol Genetics. 2005;14:845\u201357.","journal-title":"Hum Mol Genetics"},{"key":"292_CR74","first-page":"666","volume":"9","author":"U Simonsohn","year":"2014","unstructured":"Simonsohn U, Nelson LD, Simmons JP. p-Curve and Effect Size: Correcting for Publication Bias Using Only Significant Results. Perspectives on psychological science: a journal of the Association for. Psychol Sci. 2014;9:666\u201381.","journal-title":"Psychol Sci"},{"key":"292_CR75","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","volume":"86","author":"CA Chiriboga","year":"2016","unstructured":"Chiriboga CA, Swoboda KJ, Darras BT, Iannaccone ST, Montes J, De Vivo DC, et al. Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy. Neurology. 2016;86:890\u20137.","journal-title":"Neurology."},{"key":"292_CR76","doi-asserted-by":"publisher","first-page":"E2492","DOI":"10.1212\/WNL.0000000000007527","volume":"92","author":"BT Darras","year":"2019","unstructured":"Darras BT, Chiriboga CA, Iannaccone ST, Swoboda KJ, Montes J, Mignon L, et al. Nusinersen in later-onset spinalmuscular atrophy Long-term results from the phase 1\/2 studies. Neurology. 2019;92:E2492\u2013E506.","journal-title":"Neurology."},{"key":"292_CR77","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2016","unstructured":"Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016;388:3017\u201326.","journal-title":"Lancet."},{"key":"292_CR78","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N. Eng J Med. 2017;377:1723\u201332.","journal-title":"N. Eng J Med"},{"key":"292_CR79","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N. Eng J Med. 2018;378:625\u201335.","journal-title":"N. Eng J Med"},{"key":"292_CR80","doi-asserted-by":"crossref","unstructured":"van der Bent ML, da Silva OP, van Luijk J, Brock R, Wansink DG. Assisted delivery of antisense therapeutics in animal models of heritable neurodegenerative and neuromuscular disorders: a systematic review and meta-analysis. Sci Rep. 2018;8:4181.","DOI":"10.1038\/s41598-018-22316-7"},{"key":"292_CR81","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1080\/15513815.2018.1520374","volume":"38","author":"SB Qomi","year":"2019","unstructured":"Qomi SB, Asghari A, Salmaninejad A, Mojarrad M. Spinal muscular atrophy and common therapeutic advances. Fetal Pediatric Pathol. 2019;38:226\u201338.","journal-title":"Fetal Pediatric Pathol"},{"key":"292_CR82","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/gt.2017.34","volume":"24","author":"NN Singh","year":"2017","unstructured":"Singh NN, Howell MD, Androphy EJ, Singh RN. How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy. Gene Ther. 2017;24:520\u20136.","journal-title":"Gene Ther"},{"key":"292_CR83","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.4155\/fmc.15.101","volume":"7","author":"NN Singh","year":"2015","unstructured":"Singh NN, Lee BM, DiDonato CJ, Singh RN. Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy. Future Med Chem. 2015;7:1793\u2013808.","journal-title":"Future Med Chem"},{"key":"292_CR84","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.mcn.2013.04.005","volume":"56","author":"AG Douglas","year":"2013","unstructured":"Douglas AG, Wood MJ. Splicing therapy for neuromuscular disease. Mol Cell Neurosci. 2013;56:169\u201385.","journal-title":"Mol Cell Neurosci"},{"key":"292_CR85","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1089\/hum.2012.225","volume":"24","author":"PN Porensky","year":"2013","unstructured":"Porensky PN, Burghes AHM. Antisense oligonucleotides for the treatment of spinal muscular atrophy. Hum Gene Ther. 2013;24:489\u201398.","journal-title":"Hum Gene Ther"},{"key":"292_CR86","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41434-019-0085-4","volume":"26","author":"R Pattali","year":"2019","unstructured":"Pattali R, Mou YC, Li XJ. AAV9 vector: a novel modality in gene therapy for spinal muscular atrophy. Gene Ther. 2019;26:287\u201395.","journal-title":"Gene Ther"},{"key":"292_CR87","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1007\/s12325-019-00923-8","volume":"36","author":"O Dabbous","year":"2019","unstructured":"Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guerin A, et al. Survival, motor function, and motor milestones: comparison of AVXS-101 relative to nusinersen for the treatment of infants with spinal muscular atrophy type 1. Adv Ther. 2019;36:1164\u201376.","journal-title":"Adv Ther"},{"key":"292_CR88","doi-asserted-by":"publisher","unstructured":"Sandrock AW, Farwell W. Comparisons Between Separately Conducted Clinical Trials: Letter to the Editor Regarding Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Gu\u00e9rin A, et al. Adv Ther (2019) 36:1164\u201376. https:\/\/doi.org\/10.1007\/s12325-019-00923-8. Ad Ther. 2019;36:2979\u201381.","DOI":"10.1007\/s12325-019-00923-8."},{"key":"292_CR89","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nbt.1515","volume":"27","author":"KD Foust","year":"2009","unstructured":"Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol. 2009;27:59\u201365.","journal-title":"Nat Biotechnol"},{"key":"292_CR90","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/s41593-021-00827-3","volume":"24","author":"M Van Alstyne","year":"2021","unstructured":"Van Alstyne M, Tattoli I, Delestree N, Recinos Y, Workman E, Shihabuddin LS, et al. Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit. Nat Neurosci. 2021;24:930.","journal-title":"Nat Neurosci"},{"key":"292_CR91","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","volume":"74","author":"D Chand","year":"2021","unstructured":"Chand D, Mohr F, McMillan H, Tukov FF, Montgomery K, Kleyn A, et al. Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy. J Hepatol. 2021;74:560\u20136.","journal-title":"J Hepatol"},{"key":"292_CR92","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jpeds.2020.05.044","volume":"225","author":"AG Feldman","year":"2020","unstructured":"Feldman AG, Parsons JA, Dutmer CM, Veerapandiyan A, Hafberg E, Maloney N, et al. Subacute Liver Failure Following Gene Replacement Therapy for Spinal Muscular Atrophy Type 1. J Pediatrics. 2020;225:252.","journal-title":"J Pediatrics"},{"key":"292_CR93","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1089\/hum.2020.182","volume":"31","author":"JM Wilson","year":"2020","unstructured":"Wilson JM, Flotte TR. Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy. Hum Gene Ther. 2020;31:695\u20136.","journal-title":"Hum Gene Ther"},{"key":"292_CR94","doi-asserted-by":"crossref","unstructured":"Paulk N. Gene therapy: it\u2019s time to talk about high-dose AAV. 2020. https:\/\/www.genengnews.com\/commentary\/gene-therapy-its-time-to-talk-about-high-dose-aav\/.","DOI":"10.1089\/gen.40.09.04"},{"key":"292_CR95","doi-asserted-by":"crossref","unstructured":"Hao LT, Burghes AHM, Beattie CE. Generation and Characterization of a genetic zebrafish model of SMA carrying the human SMN2 gene. Mol Neurodegener. 2011;6:24.","DOI":"10.1186\/1750-1326-6-24"},{"key":"292_CR96","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1093\/hmg\/ddt110","volume":"22","author":"LT Hao","year":"2013","unstructured":"Hao LT, Duy PQ, Jontes JD, Wolman M, Granato M, Beattie CE. Temporal requirement for SMN in motoneuron development. Hum Mole Genet. 2013;22:2612\u201325.","journal-title":"Hum Mole Genet"},{"key":"292_CR97","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/mt.2009.71","volume":"17","author":"S Duque","year":"2009","unstructured":"Duque S, Joussemet B, Riviere C, Marais T, Dubreil L, Douar AM, et al. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther. 2009;17:1187\u201396.","journal-title":"Mol Ther"},{"key":"292_CR98","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/ana.24332","volume":"77","author":"SI Duque","year":"2015","unstructured":"Duque SI, Arnold WD, Odermatt P, Li XH, Porensky PN, Schmelzer L, et al. A large animal model of spinal muscular atrophy and correction of phenotype. Ann Neurol. 2015;77:399\u2013414.","journal-title":"Ann Neurol"},{"key":"292_CR99","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/mt.2014.210","volume":"23","author":"K Meyer","year":"2015","unstructured":"Meyer K, Ferraiuolo L, Schmelzer L, Braun L, McGovern V, Likhite S, et al. Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates. Mol Ther. 2015;23:477\u201387.","journal-title":"Mol Ther"},{"key":"292_CR100","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1093\/brain\/awy167","volume":"141","author":"E Janzen","year":"2018","unstructured":"Janzen E, Mendoza-Ferreira N, Hosseinibarkooie S, Schneider S, Hupperich K, Tschanz T, et al. CHP1 reduction ameliorates spinal muscular atrophy pathology by restoring calcineurin activity and endocytosis. Brain. 2018;141:2343\u201361.","journal-title":"Brain."},{"key":"292_CR101","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nrneurol.2018.4","volume":"14","author":"EJN Groen","year":"2018","unstructured":"Groen EJN, Talbot K, Gillingwater TH. Advances in therapy for spinal muscular atrophy: promises and challenges. Nat Rev Neurol. 2018;14:214\u201324.","journal-title":"Nat Rev Neurol."},{"key":"292_CR102","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ebiom.2018.04.024","volume":"31","author":"LM Walter","year":"2018","unstructured":"Walter LM, Deguise MO, Meijboom KE, Betts CA, Ahlskog N, van Westering TLE, et al. Interventions targeting glucocorticoid-kruppel-like factor 15-branched-chain amino acid signaling improve disease phenotypes in spinal muscular atrophy mice. EBioMedicine. 2018;31:226\u201342.","journal-title":"EBioMedicine."},{"key":"292_CR103","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.bbrc.2020.07.031","volume":"530","author":"KA Kaifer","year":"2020","unstructured":"Kaifer KA, Villalon E, Smith CE, Simon ME, Marquez J, Hopkins AE, et al. AAV9-DOK7 gene therapy reduces disease severity in Smn(2B\/)- SMA model mice. Biochem Biophys Res Commun. 2020;530:107\u201314.","journal-title":"Biochem Biophys Res Commun"},{"key":"292_CR104","first-page":"10","volume":"13","author":"MR Macleod","year":"2015","unstructured":"Macleod MR, McLean AL, Kyriakopoulou A, Serghiou S, de Wilde A, Sherratt N, et al. Risk of bias in reports of in vivo research: a focus for improvement. Plos Biol. 2015;13:10.","journal-title":"Plos Biol"},{"key":"292_CR105","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1161\/CIRCRESAHA.115.307676","volume":"118","author":"PP Zwetsloot","year":"2016","unstructured":"Zwetsloot PP, Vegh AMD, Jansen SJ, van Hout GPJ, Currie GL, Sena ES, et al. Cardiac stem cell treatment in myocardial infarction: a systematic review and meta-analysis of preclinical studies. Circ Res. 2016;118:1223\u201332.","journal-title":"Circ Res"},{"key":"292_CR106","first-page":"59","volume":"19","author":"TJ Jue","year":"2017","unstructured":"Jue TJ, Hirst TC, Sena ES, Macleod MR, McDonald KL. A systematic review and meta-analysis of topoisomerase inhibition in pre-clinical glioma models. Neuro-Oncology. 2017;19:59.","journal-title":"Neuro-Oncology"},{"key":"292_CR107","doi-asserted-by":"crossref","unstructured":"Tanner-Smith EE, Grant S. Meta-Analysis of Complex Interventions. Annual Review of Public Health, 2018; 39:135\u201351.","DOI":"10.1146\/annurev-publhealth-040617-014112"}],"updated-by":[{"DOI":"10.1038\/s41434-022-00377-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000}}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-021-00292-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-021-00292-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-021-00292-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T14:09:36Z","timestamp":1669644576000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-021-00292-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,6]]},"references-count":107,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["292"],"URL":"https:\/\/doi.org\/10.1038\/s41434-021-00292-4","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41434-022-00377-8","asserted-by":"object"}]},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,6]]},"assertion":[{"value":"22 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2022","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Title and caption of Table 3 have been corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2022","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41434-022-00377-8","URL":"https:\/\/doi.org\/10.1038\/s41434-022-00377-8","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}